株探米国株
日本語 英語
エドガーで原本を確認する
0000012208false00000122082024-08-152024-08-150000012208us-gaap:CommonClassAMember2024-08-152024-08-150000012208us-gaap:CommonClassBMember2024-08-152024-08-15


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report:   August 15, 2024
(Date of earliest event reported)

BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)

Commission File Number: 1-7928
 
Delaware   94-1381833
(State or other jurisdiction of incorporation)   (I.R.S. Employer Identification No.)
 
1000 Alfred Nobel Dr.
Hercules, California 94547
(Address of principal executive offices, including zip code)
 
(510)724-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, Par Value $0.0001 per share   BIO   New York Stock Exchange
Class B Common Stock, Par Value $0.0001 per share  
BIO.B
  New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   





Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 20, 2024, Bio-Rad Laboratories, Inc. (the “Company”) announced the appointment by the Board of Directors of the Company of Jonathan P. DiVincenzo as the Company’s President and Chief Operating Officer (including as principal operating officer), effective September 9, 2024.

Mr. DiVincenzo, age 59, brings more than 30 years of industry experience across strategic, operational, and commercial organizations in both life science and diagnostics. Mr. DiVincenzo joins the Company from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he was most recently Executive Vice President and President, Central Laboratories & International from May 2023 to August 2024. Prior to that, at Labcorp, he was President, Clinical Trials Testing Solutions from October 2019 to May 2023, and Senior Vice President, GM, Covance, from August 2017 to October 2019. Prior to Labcorp, from 2013 to 2016, Mr. DiVincenzo was President of the Environmental Health Division at PerkinElmer, a global company focused on diagnostics, life science research, food quality, environmental health, and industrial testing. From 2012-2013, he was CEO of Enzymatics, a privately held molecular biology reagents company. Prior to that, Mr. DiVincenzo held roles of increasing responsibility in the Biosciences and Lab Water businesses of EMD Millipore, a subsidiary of Merck KGaA. Mr. DiVincenzo holds a Bachelor of Science degree in mechanical engineering from Northeastern University.

The Company and Mr. DiVincenzo entered into an employment offer letter providing for, among other things, an annual base salary of $665,000 and a 2024 target cash bonus under the Company’s corporate incentive bonus plan of 100% of his eligible earnings. Within sixty days of his hire date, the Company’s Board will grant Mr. DiVincenzo restricted stock units valued at $2,500,000, and he also is eligible to participate in the executive long term incentive plan effective with the 2025 fiscal year, with an annual targeted grant value of $2,500,000 in 2025. The offer letter also includes a $1.3 million sign-on bonus (minus applicable taxes) payable by February 15, 2025. Mr. DiVincenzo is eligible for a housing and household goods relocation credit of up to $150,000, to be reimbursed based on submitted expenses, and for payment of his commuting costs (travel-related expenses) for up to six months to and from Indianapolis, Indiana. If, within the first 24 months of his employment, Mr. DiVincenzo voluntarily decides to leave the Company without Good Reason or is terminated for Cause, Mr. DiVincenzo will be responsible for repayment of the sign-on bonus and all relocation costs. If Mr. DiVincenzo’s employment with the Company is terminated by the Company without Cause or he resigns for Good Reason, he will be entitled to a lump sum payment equal to eighteen months of his then current annual base salary, provided that he first enters into a full release of all claims in favor of the Company, its affiliates, and their respective officers, directors and employees in a form provided by the Company. A copy of the employment offer letter entered into between the Company and Mr. DiVincenzo is filed as Exhibit 10.1 to this report.

There are no arrangements or understandings between Mr. DiVincenzo and any person other than the Company pursuant to which he was appointed as President and Chief Operating Officer. There is no family relationship between Mr. DiVincenzo and any director or executive officer of the Company or any person nominated or chosen to become a director or executive officer of the Company. Mr. DiVincenzo has no material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

A copy of the press release announcing the appointment of Mr. DiVincenzo is furnished with this report as Exhibit 99.1.

As previously disclosed, on April 10, 2024, Andrew Last, the Company’s Executive Vice President, Chief Operating Officer (and principal operating officer) notified the Company that he intends to retire from his position by early September 2024. Dr. Last will be retiring from his position on September 5, 2024.

Effective on Mr. DiVincenzo’s September 9, 2024 start date as the Company’s President and Chief Operating Officer, Norman Schwartz will continue as the Company’s Chief Executive Officer and Chairman of the Board and will no longer be the Company’s President.




Item 9.01 Financial Statements and Exhibits.
    
Exhibit Number    
Description
10.1
99.1
104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document





SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  
    BIO-RAD LABORATORIES, INC.
     
Date: August 20, 2024 By: /s/ Courtney C. Enloe
      Courtney C. Enloe
      Executive Vice President, General Counsel & Secretary


EX-10.1 2 ex101-employmentofferlette.htm EX-10.1 Document

image_0a.jpg        Exhibit 10.1

August 2, 2024

Jon DiVincenzo
10157 Hickory Ridge Drive
Zionsville, IN 46077

Dear Jon,
I am pleased to extend to you our written offer of employment to join Bio-Rad Laboratories as President & Chief Operating Officer, reporting directly to Norman Schwartz.  In your new position, your bi-weekly salary is $25,576.92 which is equivalent to $665,000 USD annually.
You are eligible to participate in our corporate Incentive Bonus Plan (IBP) with a targeted bonus of 100% of your eligible earnings in 2024, payable in Q1 2025. The terms and conditions of the IBP are contained in the plan document which you will receive at a later date.
This offer also includes a $1.3 million sign-on bonus (minus applicable taxes) payable by February 15, 2025. If within the first 24 months of your employment you voluntarily decide to leave Bio-Rad without Good reason or are terminated for Cause (both as defined in Appendix A), you will be responsible for repayment of the sign-on bonus.
You will be eligible to receive a New Hire RSU grant valued at $2.5 million within 60 days of your hire date and contingent upon approval of the Board of Directors. RSUs are typically granted under a 4-year vesting scheme with 25% of the grant vesting each anniversary of the date of grant. You are also eligible to participate in the executive Long Term Incentive Plan (LTI) effective with the 2025 fiscal year, with an annual targeted grant value of $2.5 million. It is anticipated the 2025 annual LTI will be comprised of 75% RSUs and 25% Stock Options. The terms and conditions of your grants are contained in the plan document which you will receive at a later date.
This role will require you to take residence near the Bio-Rad Corporate Headquarters within 6 months of offer acceptance. While you are looking for a local residence and to defray costs associated with localizing, we are providing you a housing and household goods relocation credit of up to $150,000, to be reimbursed based on submitted expenses. Housing and household goods expenses are defined as:
•Movement and Shipment of Household Goods
•Household Goods Storage (up to 60 days)
•Temporary Housing Accommodation (up to 60 days)
•House Hunting Trip (2 trips totaling up to 10 days)
•Final Travel (including immediate family)
•House Commission and Closing Costs
•Downpayment on a home in the San Francisco Bay Area
In addition, we will pay your commuting costs (travel related expenses) for up to 6 months to and from Indianapolis, IN. The expectation is that you will work in our Corporate Headquarters in Hercules, three weeks out of the month before you fully relocate.
You will be asked to sign a relocation repayment agreement.  In the event you voluntarily leave Bio-Rad, without Good Reason, or are terminated for Cause, within the first 24 months of your employment, you will be responsible to immediately repay the sign-on bonus in full as well as all relocation costs.



If after you begin employment with Bio-Rad you resign for Good Reason or your employment is terminated by Bio-Rad without Cause, you will be entitled to a lump sum severance payment equal to 18 months of your then current annual base provided that you first enter into a full release of all claims in favor of Bio-Rad, its affiliates and their respective officers, directors and employees in a form provided by Bio-Rad.
This offer is contingent upon your passing background and reference checks as well as a drug test prior to starting employment and entering into a mutual agreement to arbitrate with the company. The types of information that will be requested in the background check include education verification, previous employment verification, professional references, and criminal record check. Additionally, you will be asked to provide time for a courtesy interview with two our Board Members, Jeff Edwards, Chairman of the Compensation Committee and Greg Hinckley, Lead Independent
Director.
Your target start date is Monday, September 9, 2024. Please note that background checks can take up to 2 weeks to complete. We ask that you submit your information to our background check company in a timely manner to meet this proposed start date.
Bio-Rad maintains a smoke-free and drug-free work environment. As such, our expectation is that you complete a drug test. Sterling, our background screening provider, will contact you regarding a clinic location for the drug test. You must complete a drug test within five days of Sterling’s notification.
Bio-Rad’s comprehensive benefits package provides you with a variety of options that will help meet your needs. You will have up to 31 days from your start date to enroll in these benefits. If you wish to enroll your eligible dependents, you may be required to present evidence of your dependents’ eligibility, such as a marriage certificate or birth certificate. 
 
Please acknowledge your acceptance of this offer by, Wednesday, August 21, 2024. This offer is null and void after this date. Once received, a ‘Welcome to Bio-Rad’ letter will be e-mailed with details regarding your on-boarding processes and a “tentative” new hire orientation date. Please note that an official start date can't be determined until your background
has cleared.
For over 70 years, Bio-Rad has benefited from the contributions of exceptional people like you. We seek the best talent to build on the success of our company and we look forward to you joining our highly collaborative environment.  

Sincerely,
/s/ Colleen Corey
Colleen Corey
EVP, Global Human Resources
Bio-Rad Laboratories


I accept Bio-Rad Laboratories' offer of employment as herein described.
/s/ Jon DiVincenzo August 15, 2024
Jon DiVincenzo Date




APPENDIX A
Definitions

For purposes of this Offer Letter, the following definitions shall apply, with “Executive” referring to Jon DiVincenzo:
1.“Cause” shall mean:
a.The Executive’s failure to perform the Executive’s duties under the Offer Letter or as otherwise agreed to by the parties;
b.the Executive’s willful engagement in dishonesty, illegal conduct, or gross misconduct, which is, in each case, injurious to Bio-Rad or its affiliates;
c.the Executive’s embezzlement, misappropriation, or fraud, whether or not related to the Executive’s employment with Bio-Rad;
d.the Executive’s conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony (or state law equivalent) or a crime that constitutes a misdemeanor involving moral turpitude;
e.the Executive’s willful violation of Bio-Rad’s written policies or codes of conduct, including written policies related to discrimination, harassment, performance of illegal or unethical activities, and ethical misconduct;
f.the Executive’s material breach of any material obligation under the Offer Letter or any other written agreement between the Executive and Bio-Rad;
g.the Executive’s engagement in conduct (other than conduct directed by or ratified by Bio-Rad) that brings or is reasonably likely to bring Bio-Rad negative publicity or into public disgrace, embarrassment, or disrepute;
h.the Executive’s substantial dependence or addiction to any drug illegally taken or to alcohol that is in either event materially injurious to Bio-Rad.
Provided, however, that Cause will not exist with respect to any conduct or event that is curable or subject to cure, both subject to Bio-Rad’s satisfaction, unless and until (a) Bio-Rad provides Executive written notice detailing why cause exists and (b) Executive fails to cure the issue(s) raised in such notice to Bio-Rad’s satisfaction within thirty (30) days’ of his receipt of the same.
2.“Good Reason” shall mean, without Executive’s prior written consent, whether by Bio-Rad or any of its successors or assigns:
a.A material reduction in Executive’s duties, responsibilities, or title;
b.A material reduction in Executive’s compensation or benefits, except for such reduction that similarly affects other similar employees of Bio-Rad;
c.A material change in Executive’s work location; or
d.The breach by Bio-Rad of any material provision of the Offer Letter or other term and conditions of employment which is reasonably likely to cause material harm to Executive.
Provided, however, that Good Reason will not exist unless (a) Executive provides Bio-Rad written notice detailing why Good Reason exists and (b) Bio-Rad fails to cure the issue(s) raised in such notice within thirty (30) days of its receipt of the same.


EX-99.1 3 bio-8k8202024xex991.htm EX-99.1 Document


Exhibit 99.1

Press Release

Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

HERCULES, Calif.— August 20, 2024 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring.

Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company’s several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health Division at PerkinElmer, a global company focused on diagnostics, life science research, food quality, environmental health and industrial testing. He also served as Chief Executive Officer of Enzymatics, a privately held molecular biology reagents company. Prior to that, Mr. DiVincenzo held roles of increasing responsibility in the Biosciences and Lab Water businesses of EMD Millipore, a subsidiary of Merck KGaA. He holds a Bachelor of Science degree in mechanical engineering from Northeastern University.

"We are thrilled to welcome Jon DiVincenzo as our President and Chief Operating Officer,” stated Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer. “Jon brings to Bio-Rad over thirty years of industry experience across strategic, operational, and commercial organizations in both life science and clinical diagnostics. His extensive track record spans leadership roles in operations, marketing, and product development, which will be integral to our continued success.”

Mr. DiVincenzo stated, "I am excited to join Bio-Rad and I look forward to working with the executive team to continue to make progress towards achieving the company’s long-term transformational and growth objectives.”


About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,700 employees, and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.


Investor Contact:
Edward Chung, Investor Relations
510-741-6104
ir@bio-rad.com

Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
cc@bio-rad.com
1